{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:16:48Z","timestamp":1788193008327,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["5U54GM104942-08"],"award-info":[{"award-number":["5U54GM104942-08"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.japh.2026.103469","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:30:09Z","timestamp":1781713809000},"page":"103469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ensuring continuous buprenorphine access: A multicomponent quality improvement initiative in a university-affiliated clinic and outpatient pharmacy"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5640-0749","authenticated-orcid":false,"given":"Lyn Yuen","family":"Choo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-2720","authenticated-orcid":false,"given":"Wanhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-2917","authenticated-orcid":false,"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Lapkowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5745-5362","authenticated-orcid":false,"given":"Katie","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3571-0259","authenticated-orcid":false,"given":"Erin L.","family":"Winstanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2026.103469_bib1","series-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","year":"2026"},{"issue":"2","key":"10.1016\/j.japh.2026.103469_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2105\/AJPH.2018.304845","article-title":"Opioid-related outcomes in West Virginia, 2008-2016","volume":"109","author":"Warfield","year":"2019","journal-title":"Am J Public Health"},{"issue":"2","key":"10.1016\/j.japh.2026.103469_bib3","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.japh.2026.103469_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.japh.2026.103469_bib5","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/dar.70035","article-title":"Buprenorphine adherence trajectories and their impact on opioid overdose and healthcare costs","volume":"44","author":"Olateju","year":"2025","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.japh.2026.103469_bib6","article-title":"Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use","volume":"5","author":"Winstanley","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"1","key":"10.1016\/j.japh.2026.103469_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"12","key":"10.1016\/j.japh.2026.103469_bib8","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamapsychiatry.2024.3076","article-title":"Addressing the escalating problems that patients encounter when filling buprenorphine prescriptions","volume":"81","author":"Winstanley","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.japh.2026.103469_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/29767342231215178","article-title":"Relationships between stigma, risk tolerance, and buprenorphine dispensing intentions among community-based pharmacists: results from a national sample","volume":"45","author":"Light","year":"2024","journal-title":"Subst Use Addctn J"},{"issue":"1","key":"10.1016\/j.japh.2026.103469_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13722-019-0139-3","article-title":"Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence","volume":"14","author":"Godersky","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"10.1016\/j.japh.2026.103469_bib11","first-page":"5","article-title":"Outcomes for patients receiving telemedicine-delivered medication-based treatment for Opioid Use Disorder: a retrospective chart review","volume":"23","author":"Weintraub","year":"2021","journal-title":"Heroin Addict Relat Clin Probl"},{"issue":"2","key":"10.1016\/j.japh.2026.103469_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/ADM.0000000000000287","article-title":"Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective data analysis","volume":"11","author":"Zheng","year":"2017","journal-title":"J Addict Med"},{"issue":"11","key":"10.1016\/j.japh.2026.103469_bib13","article-title":"Examining the use of telehealth to initiate buprenorphine for opioid use disorder treatment","volume":"2","author":"Ge","year":"2024","journal-title":"Health Aff Sch"},{"issue":"6","key":"10.1016\/j.japh.2026.103469_bib14","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.japh.2026.103469_bib15","doi-asserted-by":"crossref","DOI":"10.24926\/iip.v12i3.4141","article-title":"Pharmacists without access to the EHR: practicing with one hand tied behind our backs","volume":"12","author":"Craddock","year":"2021","journal-title":"Innov Pharm"},{"key":"10.1016\/j.japh.2026.103469_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13722-024-00519-w","article-title":"Pharmacy-based preventive services for opioid use disorder: a survey of U.S. pharmacists","volume":"19","author":"Wu","year":"2024","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.japh.2026.103469_bib17","article-title":"Factors in rural community buprenorphine dispensing","volume":"9","author":"Major","year":"2022","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"8","key":"10.1016\/j.japh.2026.103469_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.27418","article-title":"Pharmacy barriers to receiving buprenorphine among patients undergoing telemedicine addiction treatment","volume":"8","author":"Hendy","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.japh.2026.103469_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2025.102462","article-title":"Knowledge and attitudes regarding substance use disorder treatment and harm reduction practices among US pharmacists: a scoping review","volume":"65","author":"Pope","year":"2025","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"2","key":"10.1016\/j.japh.2026.103469_bib20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.japh.2021.10.002","article-title":"Ensuring buprenorphine access in rural community pharmacies to prevent overdoses","volume":"62","author":"Ostrach","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2026.103469_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116712","article-title":"Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program","volume":"411","author":"Lander","year":"2020","journal-title":"J Neurol Sci"},{"issue":"12","key":"10.1016\/j.japh.2026.103469_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/bmjqs-2015-004411","article-title":"SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process","volume":"25","author":"Ogrinc","year":"2016","journal-title":"BMJ Qual Saf"},{"issue":"6","key":"10.1016\/j.japh.2026.103469_bib23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1037\/a0017189","article-title":"From in-session behaviors to drinking outcomes: a causal chain for motivational interviewing","volume":"77","author":"Moyers","year":"2009","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.japh.2026.103469_bib24","series-title":"Stata Statistical Software: Release 19","year":"2025"},{"issue":"1","key":"10.1016\/j.japh.2026.103469_bib25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12875-024-02609-9","article-title":"Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings","volume":"25","author":"Hooker","year":"2024","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.japh.2026.103469_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112598","article-title":"Buprenorphine adherence among a prospective cohort of homeless-experienced adults with opioid use disorder","volume":"270","author":"Fine","year":"2025","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.japh.2026.103469_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13722-024-00436-y","article-title":"Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals","volume":"19","author":"Franz","year":"2024","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"10.1016\/j.japh.2026.103469_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.9740\/mhc.2020.03.049","article-title":"Experiences and opinions of health professional students participating in an opioid use disorder educational event","volume":"10","author":"Winstanley","year":"2020","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.japh.2026.103469_bib29","article-title":"\u201cYou\u2019re not supposed to be on it forever\u201d: medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids","volume":"16","author":"Dickson-Gomez","year":"2022","journal-title":"Subst Abuse Res Treat"},{"issue":"14","key":"10.1016\/j.japh.2026.103469_bib30","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","article-title":"Intervention stigma toward medications for opioid use disorder: a systematic review","volume":"56","author":"Madden","year":"2021","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.japh.2026.103469_bib31","article-title":"Trends in mail-order prescription use among U.S. adults from 1996 to 2018: a nationally representative repeated cross-sectional study","author":"Do","year":"2020","journal-title":"medRxiv"},{"issue":"7","key":"10.1016\/j.japh.2026.103469_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5055\/jom.2021.0645","article-title":"Patient satisfaction with clinic-based medication pick up: addressing pharmacy-level challenges to buprenorphine access","volume":"17","author":"Kolb","year":"2021","journal-title":"J Opioid Manag"},{"issue":"5","key":"10.1016\/j.japh.2026.103469_bib33","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid: the impact of longer treatment on health care outcomes for opioid use disorder within a key population of Medicaid enrollees","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126004541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126004541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:38:34Z","timestamp":1788190714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319126004541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1544319126004541"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103469","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ensuring continuous buprenorphine access: A multicomponent quality improvement initiative in a university-affiliated clinic and outpatient pharmacy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103469"}}